First Drugs That Could Be Picked For Price Negotiation Showcase Longevity Of Some Brands
The first drugs expected to face US Medicare drug price negotiations, according to a new analysis, will have had an average commercial life span of 15 years.
You may also be interested in...
Stock Watch: Orphan Drug Profitability Under Threat
The difficulty of finding and retaining patients with orphan diseases translates into higher marketing costs and adds to other restrictions that limit the attractiveness of some orphan drugs. Will the IRA exacerbate matters?
Top-Selling Drugs 2022: Strong Growth In Blockbuster Ranks
COVID-19 products contributed almost a third to the global revenues from the top 20 best-selling drugs in 2022. However, strong growth was also seen for drugs across categories from immunology and cancer to HIV and cardiometabolic.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: GSK deal strengthens its infectious disease pipeline; an analysis of the first drugs subject to US Medicare price negotiations; Roche partnering head talks about strategy; promising early Alzheimer’s results for Biogen’s tau drug; and what India needs to become a world-class innovation hub.